{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T06:02:35Z","timestamp":1789970555977,"version":"4.0.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To develop and externally validate an interpretable deep learning model for pre-treatment prediction of early clinically significant immune-related adverse events in patients with hepatocellular carcinoma receiving immune checkpoint inhibitor\u2013based therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter retrospective cohort study of patients with hepatocellular carcinoma receiving immune checkpoint inhibitor\u2013based therapy, with atezolizumab plus bevacizumab serving as the representative regimen in this cohort. The study population was divided into a training cohort and an independent external validation cohort. Early immune-related adverse events were defined as clinically significant events occurring within three months after treatment initiation. Five prediction models were constructed using baseline clinical and circulating immunological variables obtained prior to treatment, including TabNet, logistic regression, random forest, extreme gradient boosting, and support vector machine models. Model performance was evaluated using discrimination, calibration, and clinical utility metrics, and model interpretability was assessed using feature attribution analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among all models, the TabNet model showed the most favorable overall performance profile, considering discrimination, calibration, clinical utility, and external validation performance. Calibration analysis showed good agreement between predicted risks and observed event rates, while decision curve analysis and clinical impact assessment indicated meaningful clinical utility across a range of threshold probabilities. Interpretability analyses identified the CD4 to CD8 ratio, serum immunoglobulin G level, albumin, platelet count, and the proportion of CD19-positive B cells as key contributors to model-predicted early immune-related adverse event risk. Risk-stratified feature clustering further suggested that immune-related features and host functional reserve may represent complementary dimensions associated with model-predicted early immune-related toxicity risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>An interpretable deep learning model was developed and externally validated for pre-treatment prediction of early clinically significant immune-related adverse events in hepatocellular carcinoma patients receiving immune checkpoint inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1886946","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:34:41Z","timestamp":1789968881000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and external validation of an interpretable deep learning model for early immune-related adverse events in hepatocellular carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Hongming","family":"Pan","sequence":"first","affiliation":[{"name":"Department of Oncology, The Affiliated Dazu Hospital of Chongqing Medical University","place":["Chongqing, China"]},{"name":"Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Dazu Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Harbin Medical University Cancer Hospital","place":["Harbin, Heilongjiang, China"]},{"name":"Department of Breast Surgery, Sixth Affiliated Hospital of Harbin Medical University","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Dazu Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guhang","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Dazu Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfeng","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Dazu Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiyu","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Oncology, The Affiliated Dazu Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-024-01549-2","article-title":"Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives","volume":"17","author":"Shen","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2478\/jtim-2024-0003","article-title":"A bibliometric analysis of immune-related adverse events in cancer patients and a meta-analysis of immune-related adverse events in patients with hepatocellular carcinoma","volume":"12","author":"Wang","year":"2024","journal-title":"J Transl Int Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115404","article-title":"Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: Influence of comorbidities and clinical outcomes","volume":"221","author":"Fortuny","year":"2025","journal-title":"Eur J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad090","article-title":"Association between immune-related adverse events and survival in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab","volume":"28","author":"Fukushima","year":"2023","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13262","article-title":"Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses","volume":"318","author":"Blum","year":"2023","journal-title":"Immunol Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70264","article-title":"Breaking barriers for intensive care admission in patients with advanced HCC on immunotherapy","volume":"45","author":"Fortuny","year":"2025","journal-title":"Liver Int"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30070498","article-title":"Molecular mechanisms of cutaneous immune-related adverse events (irAEs) induced by immune checkpoint inhibitors","volume":"30","author":"Teng","year":"2023","journal-title":"Curr Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012756","article-title":"Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade","volume":"13","author":"Guitton","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-025-00331-8","article-title":"Time dependent predictors of cardiac inflammatory adverse events in cancer patients receiving immune checkpoint inhibitors","volume":"11","author":"Sayer","year":"2025","journal-title":"Cardiooncology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1135140","article-title":"Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer","volume":"13","author":"Tao","year":"2023","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107900","article-title":"Bimodal artificial intelligence using TabNet for differentiating spinal cord tumors-Integration of patient background information and images","volume":"26","author":"Kita","year":"2023","journal-title":"iScience"},{"key":"B14","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1159\/000546574","article-title":"China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 edition)","volume":"14","author":"Zhou","year":"2025","journal-title":"Liver Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061308","article-title":"Neutrophil-to-lymphocyte ratio predicts development of immune-related adverse events and outcomes from immune checkpoint blockade: A case-control study","volume":"13","author":"Lee","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1234142","article-title":"Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3892\/ol.2024.14849","article-title":"Development of a predictive model for immune-related adverse events in patients with cancer","volume":"29","author":"Tang","year":"2024","journal-title":"Oncol Lett"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1539514","article-title":"Development and validation of nomogram models for predicting immune-related adverse events in recurrent and metastatic nasopharyngeal carcinoma patients treated with PD-L1 inhibitors","volume":"15","author":"Liu","year":"2025","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12911-021-01564-0","article-title":"Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies","volume":"21","author":"Iivanainen","year":"2021","journal-title":"BMC Med Inform Decis Mak"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1138489","article-title":"Identification and prediction of immune checkpoint inhibitors-related pneumonitis by machine learning","volume":"14","author":"Gong","year":"2023","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18010117","article-title":"A tabNet-based multidimensional deep learning model for predicting doxorubicin-induced cardiotoxicity in breast cancer patients","volume":"18","author":"Cao","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jenvman.2024.120682","article-title":"Spatial mapping of land susceptibility to dust emissions using optimization of attentive Interpretable Tabular Learning (TabNet) model","volume":"358","author":"Razavi-Termeh","year":"2024","journal-title":"J Environ Manage"},{"key":"B23","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1177\/00131644231191298","article-title":"An ensemble learning approach based on tabNet and machine learning models for cheating detection in educational tests","volume":"84","author":"Zhen","year":"2024","journal-title":"Educ Psychol Meas"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/foods12163113","article-title":"Prediction and visual analysis of food safety risk based on tabNet-GRA","volume":"12","author":"Chen","year":"2023","journal-title":"Foods"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.artmed.2025.103153","article-title":"Deep learning for early detection of chronic kidney disease stages in diabetes patients: A TabNet approach","volume":"166","author":"Chowdhury","year":"2025","journal-title":"Artif Intell Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30027-9","article-title":"CD4\/CD8 ratio and lung cancer risk","volume":"4","author":"Clifford","year":"2017","journal-title":"Lancet HIV"},{"key":"B27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13019-024-02596-z","article-title":"Prognostic significance of T lymphocyte subgroups (CD4 and CD8) in lung cancer patients after neoadjuvant chemotherapy","volume":"19","author":"Elicora","year":"2024","journal-title":"J Cardiothorac Surg"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2596","article-title":"CD4\/CD8+ T cells, DC subsets, Foxp3, and IDO expression are predictive indicators of gastric cancer prognosis","volume":"8","author":"Li","year":"2019","journal-title":"Cancer Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14349","article-title":"CD4\/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine-treated ovarian cancer patients","volume":"111","author":"Waki","year":"2020","journal-title":"Cancer Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110642","article-title":"Association of the CD4+\/CD8+ ratio with response to PD-1 inhibitor-based combination therapy and dermatological toxicities in patients with advanced gastric and esophageal cancer","volume":"123","author":"Xu","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113314","article-title":"Unveiling the impact of Cancer-IgG on glioma: Insights into biological behavior and macrophage polarization dynamics","volume":"143","author":"Han","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047362","article-title":"IgG expression in human colorectal cancer and its relationship to cancer cell behaviors","volume":"7","author":"Niu","year":"2012","journal-title":"PloS One"},{"key":"B33","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41419-019-1367-x","article-title":"Cancer cell-derived immunoglobulin G activates platelets by binding to platelet Fc\u03b3RIIa","volume":"10","author":"Miao","year":"2019","journal-title":"Cell Death Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5579-3","article-title":"Prognostic value of the CRP\/alb ratio, a novel inflammation-based score in pancreatic cancer","volume":"24","author":"Liu","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-018-0669-2","article-title":"Role of platelets and platelet receptors in cancer metastasis","volume":"11","author":"Schlesinger","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: A review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.medj.2022.12.007","article-title":"Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors","volume":"4","author":"Nu\u00f1ez","year":"2023","journal-title":"Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2022.2094772","article-title":"Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer","volume":"22","author":"Issa","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051629","article-title":"Predictive biomarkers for checkpoint inhibitor immune-related adverse events","volume":"15","author":"Les","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s13046-020-01749-x","article-title":"The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors","volume":"39","author":"Jia","year":"2020","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1886946\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:34:42Z","timestamp":1789968882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1886946\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2026.1886946"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1886946","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"article-number":"1886946"}}